BioSpace News Archive

The healthcare archiving ediscovery market has been anticipated to experience various growth prospects in the forthcoming years.

Pixium Vision SA announces the publication of a paper in Nature Communications, outlining further data with its Prima System, a photovoltaic substitute of photoreceptors providing simultaneous use of the central prosthetic and peripheral natural vision in atrophic dry age-related macular degeneration.

BerGenBio ASA and Oslo University Hospital announced the execution of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib, in hospitalised COVID-19 patients.

Nicox SA announced that members of the management team will participate in the following financial, pharmaceutical industry and scientific conferences in Europe and U.S. in the coming months: Financial and pharmaceutical Industry conferences.

RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc., has announced receipt of a first safety report from a Southwestern hospital where physicians have administered aviptadil to patients with COVID-19 respiratory failure.

BioArctic AB will publish the company’s Full Year Report for January – December 2021 on Thursday, February 3, 2022, at 08:00 a.m. CET.

Positive outcome announced for the pivotal trial for the lead pharmaceutical pipeline asset OX124, a high-dose overdose rescue medication

AlzeCure Pharma AB announced that the company’s presentation and poster regarding the research platform in neurology, Alzstatin, as presented at the 11th Symposium on Pharmaceutical Profiling in Drug Discovery and Development on January 27, 2022 in Uppsala, Sweden, are now available in its entirety on the company’s website.

The Celiac Disease Foundation, the nation’s leading patient advocacy organization for celiac disease, announces its newest appointee, Casey Guber , to its Board of Directors.

Zomedica Corp., a veterinary health company offering diagnostic and therapeutic products for companion animals, provided an update on its marketing activities during the first quarter of 2022.